NCT02935530View on ClinicalTrials.gov

Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

PHASE3CompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

October 31, 2017

Conditions
Gynecologic NeoplasmsVenous ThromboembolismLow Molecular Weight HeparinArgatroban
Interventions
DRUG

s-LMWH

2125KU, subcutaneous injection of 5-10 days

DRUG

LMWH

4250KU, subcutaneous injection of 5-10 days

DRUG

Argatroban

20mg, injection for 5-10 days

Trial Locations (1)

430000

Tongji Hospital, Wuhan

All Listed Sponsors
lead

Huazhong University of Science and Technology

OTHER

NCT02935530 - Thromboprophylaxis After Surgery for Gynecologic Malignancy in China | Biotech Hunter | Biotech Hunter